Skip to main content

Gout

      The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral…
      AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrea
      6 months 4 weeks ago
      AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrease in total urate crystal volume of the feet and ankles after AR882 75 mg once daily for 6 months. Keenan R, Abst#L15 #ACR23 @RheumNow https://t.co/gMCcSI1v9W https://t.co/lk3XQCaw0A
      In case you missed it!

      AR882-selective oral URAT1i added to #allopurinol rapidly improves/dissolve #tophi. Given with #
      6 months 4 weeks ago
      In case you missed it! AR882-selective oral URAT1i added to #allopurinol rapidly improves/dissolve #tophi. Given with #colchicine, #placebo 3/4 flared vs <1/2 w drug. My critique is why not optimize allopurinol dose - only 300 mg, no fuboxastat L15 #ACR23 @RheumNow @ACRheum https://t.co/NZWLpWXT51
      US adults with #gout had higher 10-year all-cause mortality rates than those without

      Premature mortality in gout
      ➡?
      6 months 4 weeks ago
      US adults with #gout had higher 10-year all-cause mortality rates than those without Premature mortality in gout ➡️Has not improved over time despite improved survival in the general population ➡️Worse among women ➡️Worse among Black individuals #ACR23 👉🏽https://t.co/NDCIhKfCNL https://t.co/uKCswHKU0n
      Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely
      6 months 4 weeks ago
      Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
      McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independe
      6 months 4 weeks ago
      McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT
      Gout mortality
      A#2428 #ACR23 @RheumNow
      1988-1994 (early) v 2007-2016 (late): Has not improved over time
      Independent of s
      6 months 4 weeks ago
      Gout mortality A#2428 #ACR23 @RheumNow 1988-1994 (early) v 2007-2016 (late): Has not improved over time Independent of serum uric acid Female gout: increased mortality Black gout pts also increased Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu
      #ACR23

      #SGLT2 inhibitors assoc with
      ⬇️ urate
      ⬇️ flares if #gout
      ⬇️mortality

      impact on #metabolicSyndrome
      7 months ago
      #ACR23 #SGLT2 inhibitors assoc with ⬇️ urate ⬇️ flares if #gout ⬇️mortality impact on #metabolicSyndrome ✅ https://t.co/ZIqDqirqar